ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
Company profile
Ticker
CCXI
Exchange
Website
CEO
Thomas Schall
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
ChemoCentryx Limited • ChemoCentryx Ireland Limited ...
IRS number
943254365
CCXI stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
31 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Oct 22
POSASR
Automatic shelf registration (post-effective amendment)
20 Oct 22
8-K
Amgen Successfully Completes Acquisition of Chemocentryx
20 Oct 22
25-NSE
Exchange delisting
20 Oct 22
8-K
Submission of Matters to a Vote of Security Holders
18 Oct 22
DEFA14A
Additional proxy soliciting materials
7 Oct 22
DEFA14A
Additional proxy soliciting materials
19 Sep 22
8-K
Other Events
19 Sep 22
Transcripts
CCXI
Earnings call transcript
2022 Q1
6 May 22
CCXI
Earnings call transcript
2021 Q4
2 Mar 22
CCXI
Earnings call transcript
2021 Q3
10 Nov 21
CCXI
Earnings call transcript
2021 Q2
10 Aug 21
CCXI
Earnings call transcript
2021 Q1
30 Apr 21
CCXI
Earnings call transcript
2020 Q4
2 Mar 21
CCXI
Earnings call transcript
2020 Q3
10 Nov 20
CCXI
Earnings call transcript
2020 Q2
11 Aug 20
CCXI
Earnings call transcript
2020 Q1
13 May 20
CCXI
Earnings call transcript
2019 Q4
11 Mar 20
Latest ownership filings
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 45.48 mm | 45.48 mm | 45.48 mm | 45.48 mm | 45.48 mm | 45.48 mm |
Cash burn (monthly) | (no burn) | 2.73 mm | 10.52 mm | 10.97 mm | 8.71 mm | 4.46 mm |
Cash used (since last report) | n/a | 59.88 mm | 230.50 mm | 240.29 mm | 190.73 mm | 97.64 mm |
Cash remaining | n/a | -14.40 mm | -185.03 mm | -194.82 mm | -145.25 mm | -52.16 mm |
Runway (months of cash) | n/a | -5.3 | -17.6 | -17.8 | -16.7 | -11.7 |
Institutional ownership, Q2 2023
16.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 259.95 mm |
Total shares | 11.88 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 6.69 mm | $72.96 mm |
Vifor | 5.19 mm | $186.99 mm |